CERo Therapeutics Holdings ( (CERO) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo Therapeutics Holdings, Inc. has notified investors that it will be late filing its Annual Report on Form 10-K (Yearly Report) for the year ended December 31, 2025. The disclosure comes via a Form 12b-25, covering its financial results for the 2025 fiscal year.
The company cites the recent appointment of a new independent registered public accounting firm in February 2026 as the key reason for the delay. The new auditor needs more time to complete its review of CERo’s 2025 financial statements, and management says the filing could not be completed without unreasonable effort or expense.
CERo states that it expects to submit the Form 10-K (Yearly Report) no later than the fifteenth calendar day after the original March 31, 2026 deadline. This timetable is in line with the grace period allowed under SEC rules when a Form 12b-25 is filed.
Preliminary figures show a sharp increase in the company’s net loss to an estimated $19.9 million for 2025, up from $8.3 million in 2024. Management attributes the deeper loss mainly to higher operating expenses tied to expanded pre-clinical and clinical activities after FDA approval of the IND for its lead program, alongside lower other income.
The company also reports that cash used in operating activities rose to $16.2 million in 2025, compared with $12.9 million the year before, underscoring heavier cash burn as its development programs advance. CERo emphasizes that these numbers are preliminary, unaudited, and could change once year-end closing and audit procedures are completed.
The filing contains the usual forward-looking statements language, warning that timing of the Form 10-K (Yearly Report) and the preliminary results are subject to risks and uncertainties. Investors are reminded that actual outcomes may differ materially as the audit is finalized and internal control procedures are fully executed.
CERo notes that it is current on all other required SEC filings and is working closely with its new auditors to complete the annual reporting process. The notification is signed on behalf of the company by Chief Executive Officer Chris Ehrlich, dated April 1, 2026, signaling management’s formal commitment to resolve the delay and remain in compliance.
The most recent analyst rating on (CERO) stock is a Hold with a $0.10 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
Average Trading Volume: 528,409
Technical Sentiment Signal: Strong Sell
Current Market Cap: $738.6K
Find detailed analytics on CERO stock on TipRanks’ Stock Analysis page.